EGFR and non-small cell lung carcinoma: EGFR mutations (particularly T790M and L858R double mutation) are known as a major cause of EGFR signaling hyperactivation and EGFR-targeted drug acquired resistance in many cancers, especially in non-small cell lung carcinoma (NSCLC) [39, 40].